An optical labeling-based proliferation assay system reveals the paracrine effect of interleukin-6 in breast cancer

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1853, Issue 1, 2015, Pages 27-40

  Itou, Junji ^a   Tanaka, Sunao ^a   Sato, Fumiaki ^a   Akiyama, Ryutaro ^b,c   Kawakami, Yasuhiko ^b,c   Toi, Masakazu ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Breast cancer; Interleukin 6; Optical labeling; Paracrine effect; Proliferation; The OPA system

Indexed keywords

INTERLEUKIN 6; IL6 PROTEIN, HUMAN; KAEDE PROTEIN, TRACHYPHYLLIA GEOFFROYI; PHOTOPROTEIN;

ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER; CANCER CELL; CELL DIVISION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; FLUORESCENCE; IRRADIATION; PARACRINE SIGNALING; BREAST TUMOR; DIAGNOSTIC USE; FEMALE; HUMAN; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; INTERLEUKIN-6; LUMINESCENT PROTEINS; PARACRINE COMMUNICATION;

EID: 84908191146     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.10.004     Document Type: Article

References (48)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Whitfield M.L., George L.K., Grant G.D., Perou C.M. Common markers of proliferation. Nat. Rev. Cancer 2006, 6:99-106.
3. Adjei A.A., Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J. Clin. Oncol. 2005, 23:5386-5403.
4. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10:789-799.
5. Santarius T., Shipley J., Brewer D., Stratton M.R., Cooper C.S. A census of amplified and overexpressed human cancer genes. Nat. Rev. Cancer 2010, 10:59-64.
6. Timp W., Feinberg A.P. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat. Rev. Cancer 2013, 13:497-510.
7. Eroles P., Bosch A., Pérez-Fidalgo J.A., Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat. Rev. 2012, 38:698-707.
8. Niepel M., Hafner M., Pace E.A., Chung M., Chai D.H., Zhou L., Muhlich J.L., Schoeberl B., Sorger P.K. Analysis of growth factor signaling in genetically diverse breast cancer lines. BMC Biol. 2014, 12:20.
9. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lønning P.E., Børresen-Dale A.L., Brown P.O., Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
10. Parker J.S., Mullins M., Cheang M.C., Leung S., Voduc D., Vickery T., Davies S., Fauron C., He X., Hu Z., Quackenbush J.F., Stijleman I.J., Palazzo J., Marron J.S., Nobel A.B., Mardis E., Nielsen T.O., Ellis M.J., Perou C.M., Bernard P.S. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 2009, 27:1160-1167.
11. Kao J., Salari K., Bocanegra M., Choi Y.L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D., Pollack J.R. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 2009, 4:e6146.
12. Guo Y., Xu F., Lu T., Duan Z., Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat. Rev. 2012, 38:904-910.
13. Kojima H., Inoue T., Kunimoto H., Nakajima K. IL-6-STAT3 signaling and premature senescence. Jak-stat 2013, 2:e25763.
14. Lieblein J.C., Ball S., Hutzen B., Sasser A.K., Lin H.J., Huang T.H., Hall B.M., Lin J. STAT3 can be activated through paracrine signaling in breast epithelial cells. BMC Cancer 2008, 8:302.
15. Marotta L.L.C., Almendro V., Marusyk A., Shipitsin M., Schemme J., Walker S.R., Bloushtain-Qimron N., Kim J.J., Choudhury S.A., Maruyama R., Wu Z., Gönen M., Mulvey L.A., Bessarabova M.O., Huh S.J., Silver S.J., Kim S.Y., Park S.Y., Lee H.E., Anderson K.S., Richardson A.L., Nikolskaya T., Nikolsky Y., Liu X.S., Root D.E., Hahn W.C., Frank D.A., Polyak K. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 2011, 121:2723-2735.
16. Sansone P., Storci G., Tavolari S., Guarnieri T., Giovannini C., Taffurelli M., Ceccarelli C., Santini D., Paterini P., Marcu K.B., Chieco P., Bonafè M. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 2007, 117:3988-4002.
17. Dethlefsen C., Højfeldt G., Hojman P. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res. Treat. 2013, 138:657-664.
18. Miyawaki A. Fluorescent proteins in a new light. Nat. Biotechnol. 2004, 22:1374-1376.
19. McKinney S.A., Murphy C.S., Hazelwood K.L., Davidson M.W., Looger L.L. A bright and photostable photoconvertible fluorescent protein. Nat. Methods 2009, 6:131-133.
20. Ando R., Hama H., Yamamoto-Hino M., Mizuno H., Miyawaki A. An optical marker based on the UV-induced green-to-red photoconversion of a fluorescent protein. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:12651-12656.
21. Itou J., Matsumoto Y., Yoshikawa K., Toi M. Sal-like 4 (SALL4) suppresses CDH1 expression and maintains cell dispersion in basal-like breast cancer. FEBS Lett. 2013, 587:3115-3121.
22. Itou J., Kawakami H., Quach T., Osterwalder M., Evans S.M., Zeller R., Kawakami Y. Islet1 regulates establishment of the posterior hindlimb field upstream of the Hand2-Shh morphoregulatory gene network in mouse embryos. Development 2012, 139:1620-1629.
23. Itou J., Oishi I., Kawakami H., Glass T.J., Richter J., Johnson A., Lund T.C., Kawakami Y. Migration of cardiomyocytes is essential for heart regeneration in zebrafish. Development 2012, 139:4133-4142.
24. Maltzman W., Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 1984, 4:1689-1694.
25. Trautinger F., Kindås-Mügge I., Knobler R.M., Hönigsmann H. Stress proteins in the cellular response to ultraviolet radiation. J. Photochem. Photobiol. B Biol. 1996, 35:141-148.
26. Latonen L., Laiho M. Cellular UV damage responses-functions of tumor suppressor p53. Biochim. Biophys. Acta 2005, 1755:71-89.
27. Faraji S., Dreuw A. Physicochemical mechanism of light-driven DNA repair by (6-4) photolyases. Annu. Rev. Phys. Chem. 2014, 65:275-292.
28. Mori T., Nakane M., Hattori T., Matsunaga T., Ihara M., Nikaido O. Simultaneous establishment of monoclonal antibodies specific for either cyclobutane pyrimidine dimer or (6-4)photoproduct from the same mouse immunized with ultraviolet-irradiated DNA. Photochem. Photobiol. 1991, 54:225-232.
29. Haapajärvi T., Kivinen L., Heiskanen A., des Bordes C., Datto M.B., Wang X.F., Laiho M. UV radiation is a transcriptional inducer of p21(Cip1/Waf1) cyclin-kinase inhibitor in a p53-independent manner. Exp. Cell Res. 1999, 248:272-279.
30. Studebaker A.W., Storci G., Werbeck J.L., Sansone P., Sasser A.K., Tavolari S., Huang T., Chan M.W., Marini F.C., Rosol T.J., Bonafé M., Hall B.M. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res. 2008, 68:9087-9095.
31. Sakaue-Sawano A., Kurokawa H., Morimura T., Hanyu A., Hama H., Osawa H., Kashiwagi S., Fukami K., Miyata T., Miyoshi H., Imamura T., Ogawa M., Masai H., Miyawaki A. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 2008, 132:487-498.
32. Hesse M., Raulf A., Pilz G.A., Haberlandt C., Klein A.M., Jabs R., Zaehres H., Fügemann C.J., Zimmermann K., Trebicka J., Welz A., Pfeifer A., Röll W., Kotlikoff M.I., Steinhäuser C., Götz M., Schöler H.R., Fleischmann B.K. Direct visualization of cell division using high-resolution imaging of M-phase of the cell cycle. Nat. Commun. 2012, 3:1076.
33. Kang B., Austin L.A., El-Sayed M.A. Real-time molecular imaging throughout the entire cell cycle by targeted plasmonic-enhanced Rayleigh/Raman spectroscopy. Nano Lett. 2012, 12:5369-5375.
34. Tomura M., Yoshida N., Tanaka J., Karasawa S., Miwa Y., Miyawaki A., Kanagawa O. Monitoring cellular movement in vivo with photoconvertible fluorescence protein "Kaede" transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10871-10876.
35. Moon H.Y., Kim O.H., Kim H.T., Choi J.H., Yeo S.Y., Kim N.S., Park D.S., Oh H.W., You K.H., De Zoysa M., Kim C.H. Establishment of a transgenic zebrafish EF1alpha:Kaede for monitoring cell proliferation during regeneration. Fish Shellfish Immunol. 2013, 34:1390-1394.
36. Sottocornola R., Lo Celso C. Dormancy in the stem cell niche. Stem Cell Res. Ther. 2012, 3:10.
37. Tamm I., Cardinale I., Krueger J., Murphy J.S., May L.T., Sehgal P.B. Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells. J. Exp. Med. 1989, 170:1649-1669.
38. Danforth D.N., Sgagias M.K. Interleukin-1 alpha and interleukin-6 act additively to inhibit growth of MCF-7 breast cancer cells in vitro. Cancer Res. 1993, 53:1538-1545.
39. Badache A., Hynes N.E. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res. 2001, 61:383-391.
40. Underhill-Day N., Heath J.K. Oncostatin M (OSM) cytostasis of breast tumor cells: characterization of an OSM receptor beta-specific kernel. Cancer Res. 2006, 66:10891-10901.
41. Chiu J.J., Sgagias M.K., Cowan K.H. Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin. Cancer Res. 1996, 2:215-221.
42. Douglas A.M., Goss G.A., Sutherland R.L., Hilton D.J., Berndt M.C., Nicola N.A., Begley C.G. Expression and function of members of the cytokine receptor superfamily on breast cancer cells. Oncogene 1997, 14:661-669.
43. Ásgeirsson K.S., Ólafsdóttir K., Jónasson J.G., Ögmundsdóttir H.M. The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer. Cytokine 1998, 10:720-728.
44. Morinaga Y., Suzuki H., Takatsuki F., Akiyama Y., Taniyama T., Matsushima K., Onozaki K. Contribution of IL-6 to the antiproliferative effect of IL-1 and tumor necrosis factor on tumor cell lines. J. Immunol. 1989, 143:3538-3542.
45. Johnston P.G., Rondinone C.M., Voeller D., Allegra C.J. Identification of a protein factor secreted by 3T3-L1 preadipocytes inhibitory for the human MCF-7 breast cancer cell line. Cancer Res. 1992, 52:6860-6865.
46. Leslie K., Gao S.P., Berishaj M., Podsypanina K., Ho H., Ivashkiv L., Bromberg J. Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation. Breast Cancer Res. 2010, 12:R80.
47. Sasser A.K., Sullivan N.J., Studebaker A.W., Hendey L.F., Axel A.E., Hall B.M. Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. FASEB J. 2007, 21:3763-3770.
48. Jiang X.P., Yang D.C., Elliott R.L., Head J.F. Down-regulation of expression of interleukin-6 and its receptor results in growth inhibition of MCF-7 breast cancer cells. Anticancer Res 2011, 31:2899-2906.